Department of Neurology, Great Ormond Street Hospital for Children, London, United Kingdom.
Department of Neuroradiology, Great Ormond Street Hospital for Children, London, United Kingdom.
JAMA Neurol. 2020 Nov 1;77(11):1440-1445. doi: 10.1001/jamaneurol.2020.2687.
Neurological manifestations have been reported in adults with coronavirus disease 2019 (COVID-19), which is caused by the highly pathogenic virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
To report the neurological manifestations of children with COVID-19.
DESIGN, SETTING, AND PARTICIPANTS: In this case-series study, patients younger than 18 years who presented with SARS-CoV-2 infection and neurological symptoms to Great Ormond Street Hospital for Children (London, UK) between March 1, 2020, and May 8, 2020, were included after infection was confirmed by either a quantitative reverse transcription-polymerase chain reaction assay by nasopharyngeal swab or a positive test result for IgG antibodies against SARS-CoV-2 in serum.
Clinical and paraclinical features were retrieved from electronic patient records.
Of the 27 children with COVID-19 pediatric multisystem inflammatory syndrome, 4 patients (14.8%) who were previously healthy had new-onset neurological symptoms. Symptoms included encephalopathy, headaches, brainstem and cerebellar signs, muscle weakness, and reduced reflexes. All 4 patients required intensive care unit admission for the treatment of COVID-19 pediatric multisystem inflammatory syndrome. Splenium signal changes were seen in all 4 patients on magnetic resonance imaging of the brain. In the 2 patients whose cerebrospinal fluid was tested, samples were acellular, with no evidence of infection on polymerase chain reaction or culture (including negative SARS-CoV-2 polymerase chain reaction results) and negative oligoclonal band test results. In all 3 patients who underwent electroencephalography, a mild excess of slow activity was found. Tests for N-methyl-d-aspartate receptor, myelin oligodendrocyte glycoprotein, and aquaporin-4 autoantibodies had negative results in all patients. In all 3 patients who underwent nerve conduction studies and electromyography, mild myopathic and neuropathic changes were seen. Neurological improvement was seen in all patients, with 2 making a complete recovery by the end of the study.
In this case-series study, children with COVID-19 presented with new neurological symptoms involving both the central and peripheral nervous systems and splenial changes on imaging, in the absence of respiratory symptoms. Additional research is needed to assess the association of neurological symptoms with immune-mediated changes among children with COVID-19.
由高致病性病毒严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引起的 2019 年冠状病毒病(COVID-19)已在成人中报告了神经系统表现。
报告 COVID-19 患儿的神经系统表现。
设计、地点和参与者:在这项病例系列研究中,纳入 2020 年 3 月 1 日至 2020 年 5 月 8 日期间因 SARS-CoV-2 感染并出现神经系统症状而前往英国伦敦大奥蒙德街儿童医院的年龄小于 18 岁的患者,在通过鼻咽拭子的定量逆转录-聚合酶链反应检测或血清中 SARS-CoV-2 抗体 IgG 阳性检测结果确认感染后,将这些患者纳入研究。
从电子病历中检索临床和临床前特征。
在 27 例患有 COVID-19 儿科多系统炎症综合征的儿童中,4 例(14.8%)既往健康的患儿出现新发神经系统症状。症状包括脑病、头痛、脑干和小脑体征、肌肉无力和反射减弱。所有 4 例患儿均因 COVID-19 儿科多系统炎症综合征而需要入住重症监护病房。4 例患儿的脑部磁共振成像均显示胼胝体信号改变。在接受脑脊液检测的 2 例患儿中,样本无细胞,聚合酶链反应或培养物无感染证据(包括 SARS-CoV-2 聚合酶链反应结果阴性),寡克隆带检测结果也为阴性。在所有 3 例行脑电图检查的患儿中,均发现轻度慢波活动过多。对 N-甲基-D-天冬氨酸受体、髓鞘少突胶质细胞糖蛋白和水通道蛋白-4 自身抗体的检测结果在所有患儿中均为阴性。在所有 3 例行神经传导研究和肌电图检查的患儿中,均发现轻度肌病和神经病改变。所有患儿的神经系统症状均有改善,其中 2 例在研究结束时完全康复。
在这项病例系列研究中,患有 COVID-19 的儿童出现了新的神经系统症状,涉及中枢和外周神经系统,并伴有影像学上的胼胝体改变,而无呼吸系统症状。需要进一步研究以评估 COVID-19 患儿的神经系统症状与免疫介导变化之间的关联。